TCS-OX2-29
CAS: 372523-75-6
Ref. 3D-XPA52375
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar | ||
| 50mg | A consultar | ||
| 100mg | A consultar |
Información del producto
- 1-Butanone, 1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-[(4-pyridinylmethyl)amino]-, (2S)-
- (2S)-2-(4-Pyridylmethylamino)-1-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)-3,3-dimethylbutan-1-one
- (2S)-1-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-[(4-pyridinylmethyl)amino]-1-butanone
- Isoquinoline, 2-[(2S)-3,3-dimethyl-1-oxo-2-[(4-pyridinylmethyl)amino]butyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-
- TCS-OX 2-29
TCS-OX2-29 is a novel nicotinic acetylcholine receptor (nAChR) ligand that binds to the ventral and rostral ventrolateral tegmental areas of the brain. It has been shown to have an excitatory effect in animal models and was found to increase locomotor activity in rats. TCS-OX2-29 has been evaluated for its potential interaction with other compounds, including nicotine, which is used as a model for nAChR agonists. TCS-OX2-29 has been shown to be effective at doses of 20 mg/kg or higher when administered chronically over a period of ten days.
Propiedades químicas
Consulta técnica sobre: 3D-XPA52375 TCS-OX2-29
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
